Sotera Health Company Up 12.95% To $14.30 After Earnings Beat

Sotera Health Co (SHC) surpassed earnings projections on 11/1/2023 for Q3 2023.

Sotera Health Company's earnings came in at an EPS of $0.21 per share, 5.00% higher than estimates for an EPS of $0.2 per share. The firm's earnings are down 9% since reporting $0.23 per share in the same period a year ago. Remember, earnings reported were on an adjusted basis, so they may not be comparable to prior reports and/or analyst estimates.

Revenues were downbeat at $263.2 million. That is an increase of 5.82% in revenues from the year-ago report and is 0.52% lower than consensus estimates set at $264.6 million.

The stock is up 12.95% to $14.30 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

The average recommendation from Wall Street analysts was a Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Sotera Health Company has performed a little above average during the past few months. Before the report, Sotera Health Company received a Long-Term Technical Rank by InvestorsObserver of 68, putting it in the top half of stocks. The firm set a 52-week high on July 19, 2023 at $19.4 and set a 52-week low on November 9, 2022 at $5.78.

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are United States, Canada, Europe, and other regions.